News
BMS/Celgene merger payout evaporates as CVR deadline passes
Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three late-stage drugs saw their hopes dashed as 2020 drew to a close.
